Genelux Corporation

NasdaqCM GNLX

Genelux Corporation Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 29,465,105

Genelux Corporation Shares (Diluted, Weighted) is 29,465,105 for the Trailing 12 Months (TTM) ending September 30, 2024, a 15.98% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Genelux Corporation Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 25,405,089, a -11.73% change year over year.
Genelux Corporation Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 28,781,289, a 18.31% change year over year.
Genelux Corporation Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 24,327,516.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: GNLX

Genelux Corporation

CEO	Mr. Thomas Zindrick J.D.
IPO Date	Jan. 26, 2023
Location	United States
Headquarters	2625 Townsgate Road
Employees	24
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Key trends

Past 5 years